Home » AEterna Zentaris: Cetrorelix Trial Meets Primary Endpoint
AEterna Zentaris: Cetrorelix Trial Meets Primary Endpoint
AEterna Zentaris Inc. … reported that the 043 Thorough QT trial, which is part of the cetrorelix pamoate clinical development program in benign prostatic hyperplasia, met its primary endpoint.
Earth Times
Earth Times
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May